Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Real-time Quote. Real-time Tradegate - 08/29 04:48:23 pm
69.435 EUR   +0.12%
03:05p Mylan to launch generic EpiPen at half the price of original
09:30aSANOFI : Back on a long term support level
09:29aDJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Mylan to launch generic EpiPen at half the price of original

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/29/2016 | 03:05pm CEST

Mylan NV (>> Mylan NV) said it would launch the first generic version of its allergy auto-injector EpiPen at half the price of the branded product, the drugmaker's second step in less than a week to counter a wave of criticism over the product's high price.

Mylan NV (>> Mylan NV) said it would launch the first generic version of its allergy auto-injector EpiPen at half the price of the branded product, the drugmaker's second step in less than a week to counter a wave of criticism over the product's high price.

The company reduced the out-of-pocket costs of EpiPen for some patients last week, but kept the list price at about $600, a move that lawmakers said was not enough. EpiPen cost about $100 in 2008.

Mylan said on Monday it expected to launch the generic product "in several weeks" at a list price of $300, an highly unusual move considering the branded product is still under patent protection and rival treatments have failed to get regulatory clearances.

Chief Executive Heather Bresch has defended EpiPen's high price, saying Mylan had spent hundreds of millions of dollars improving the product, including making the needle invisible, since acquiring it from Germany's Merck KGaA (>> Merck KGaA).

The company has said that it recoups less than half of EpiPen's list price because pharmacy benefit managers, which often require discounted prices or rebates from drugmakers, are involved, along with insurers and others.

"Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response," Bresch said on Monday. "We determined that bypassing the brand system in this case and offering an additional alternative was the best option."

Netherlands-based Mylan said it also intends to continue to market and distribute branded EpiPen.

EpiPen is a preloaded injection of epinephrine (adrenaline) used in case of a dangerous allergic reaction known as anaphylaxis that could cause death if untreated.

Anaphylaxis can occur in as little as a couple of minutes of exposure to the allergen, which can come in the form of food such as peanuts or insects such as bees.

U.S. health regulators rejected Adamis Pharmaceuticals Corp's (>> Adamis Pharmaceuticals Corp) rival treatment to EpiPen in June. Sanofi (>> Sanofi) has pulled its device from the market and Teva Pharmaceutical Industries Ltd (>> Teva Pharmaceutical Industries Limited) was forced to delay the launch of its version.

Mylan is the latest company to be caught up in the growing outrage, including from Presidential candidate Hillary Clinton, at apparently egregious drug price increases.

Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) and privately held Turing Pharmaceuticals have both been publicly excoriated for similar price increases.

Mylan's shares were up about 2 percent at $43.90 in premarket trading. The stock had fallen 12 percent last week.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D'Souza)

By Ankur Banerjee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
03:05p Mylan to launch generic EpiPen at half the price of original
09:29aDJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08:01a SANOFI : Regeneron and Sanofi Present Positive Phase 3 Investigational Data for ..
08:01a SANOFI : and Regeneron Present Positive Phase 3 Investigational Data for Praluen..
08/25 SANOFI : Researchers from Sanofi Aventis Report Findings in Hepatic Encephalopat..
08/25 DÉPAKINE : 14 300 femmes enceintes seront indemnisées
08/24 SANOFI : Haiti Impact Trip Provides Eye-Opening Experience for Stop Hunger Now P..
08/22 MEDIVATION : Pfizer propose 14 milliards de dollars pour racheter Medivation
08/22 Pfizer to buy cancer drugmaker Medivation for $14 billion
08/22 Pfizer to buy Medivation and boost cancer drug portfolio
More news
Sector news : Pharmaceuticals - NEC
03:05p Mylan to launch generic EpiPen at half the price of original
01:56pDJMYLAN : Feeling Heat on EpiPen Price, Will Offer Cheaper Generic
11:29aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
11:10aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test
08/27 Stada shareholder AOC pushes through board reshuffle
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08:34a Late-stage study shows Sanofi/Regeneron's Praluent delivers substantial treat..
03:43a Hate The Game, Not The Player? - Mylan Is Out Of Tune Amid An Angry Chorus
08/28 Singapore confirms locally transmitted Zika cases
08/26 FDA recommends Zika screening of blood components in all states and territori..
08/26 Updating My Price Target On Pfizer
Advertisement
Financials (€)
Sales 2016 36 960 M
EBIT 2016 9 286 M
Net income 2016 5 309 M
Debt 2016 5 008 M
Yield 2016 4,25%
P/E ratio 2016 15,83
P/E ratio 2017 14,42
EV / Sales 2016 2,55x
EV / Sales 2017 2,55x
Capitalization 89 393 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 84,5 €
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-11.77%100 075
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-12.84%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-10.83%210 234
ASTRAZENECA PLC7.33%173 797
More Results